Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.
Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript
Perrigo (PRGO) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.6 per share a year ago.
Mitigating category headwinds with market share gains through implementation of Three‑S plan. Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed ® , Opill ® , and ellaOne ® brands.
Advances key Three-S plan pillar, streamlining portfolio Upfront net proceeds of approximately €306 million will enable debt reduction DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years.
ICU Medical (ICUI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN, April 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.
Perrigo sports a forward dividend yield nearing 10%, but this high yield is highly reflective of high uncertainty over the company's future performance. Despite a mixed dividend growth track record, an ongoing catalyst may make Healthpeak Properties appealing to investors focused on capital growth.
DUBLIN, April 22, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer health products, today announced that it plans to issue its first quarter 2026 financial results on Wednesday, May 6, 2026, and host a conference call beginning at 8:30 A.M. (EST). The earnings conference call will be available live via webcast in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 82404.
The S&P 600 Small Cap index offers exposure to quality small-cap stocks with earnings requirements, providing growth potential and less analyst coverage. Eight S&P 600 small-cap dividend stocks meet the 'IDEAL' criteria: dividends from $1K invested exceed share price and free cash flow supports payouts. Top ten S&P 600 small-cap dividend dogs are projected to deliver an average 64.97% net gain by April 2027, with above-market volatility.
SG Americas Securities LLC boosted its holdings in shares of Perrigo Company plc (NYSE: PRGO) by 1,495.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 134,433 shares of the company's stock after buying an additional 126,008 shares during
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings and
Perrigo offers a compelling value with a 12% dividend yield and a P/E of 4.3, trading at a deep discount to fair value. PRGO is refocused on its core OTC store-brand business, prioritizing cost savings and operational efficiencies after divestitures and past acquisition missteps. Management's Three-S Plan targets $80M–$100M in annual cost savings by 2027, supporting margin improvement and sustainable dividend growth.
O Keefe Stevens Advisory Inc. decreased its position in Perrigo Company plc (NYSE: PRGO) by 25.2% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 167,803 shares of the company's stock after selling 56,600 shares during the quarter. Perrigo
Investors love ultra-high-yield dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.
Perrigo Company plc (PRGO) Presents at UBS Global Consumer and Retail Conference Transcript
Dimensional Fund Advisors LP raised its position in Perrigo Company plc (NYSE: PRGO) by 2.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,695,238 shares of the company's stock after buying an additional 181,828 shares during the period.
Citigroup Inc. raised its position in shares of Perrigo Company plc (NYSE: PRGO) by 110.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 89,197 shares of the company's stock after purchasing an additional 46,848 shares during the quarter. Citigroup
United-Guardian (NASDAQ: UG - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk. Valuation and Earnings This table compares United-Guardian and Perrigo"s
What's better than getting to buy 6.6%-11% yields at discounted prices?